Fedratinib Uses, Dosage, Side Effects and Interactions
Inrebic
Inrebic was the first fedratinib product the FDA approved, in August 2019. No generic is listed as capsules.
Fedratinib is a once-daily oral kinase inhibitor used to treat adults with intermediate-2 or high-risk primary or secondary myelofibrosis, a bone marrow disorder.
Quick links
Ask Anything About FedratinibType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Fedratinib in Short
What it treatsFedratinib (sold as Inrebic) treats adults with intermediate-2 or high-risk myelofibrosis. This includes primary myelofibrosis and secondary myelofibrosis that developed after polycythemia vera or essential thrombocythemia.
- How you get it Prescription only
- Comes asCapsule (by mouth)
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
- Supplements and herbs177 interact 6 major, 132 moderate and 39 minor
- Generic launch2033 to 2034 Our estimate for the first generic of Inrebic
The Pharmacist’s Take
Fedratinib (Inrebic) is a JAK2 inhibitor that blocks an overactive enzyme driving myelofibrosis (a bone marrow disease) in adults with intermediate-2 or high-risk disease; it is a specialist drug, used first or after ruxolitinib, on the market since about 2019 and not available as a generic. Stomach upset is the main complaint (diarrhea, nausea, vomiting), and tiredness and low red cell and platelet counts are common too. The boxed warning is for encephalopathy, including Wernicke's, a brain emergency tied to low thiamine (vitamin B1); confusion, memory trouble, unsteady walking or double vision need emergency care. Never stop it suddenly on your own, since symptoms can flare.
Key Takeaways From the HelloPharmacist Team
- Take it once a day with or without food, and if you miss a dose, just take the next day's dose.
- Take a thiamine (vitamin B1) supplement every day, and expect regular blood tests for thiamine, blood counts and liver and pancreas enzymes.
- Have an anti-nausea and anti-diarrhea medicine on hand from day one, and call your doctor if diarrhea or vomiting lasts beyond 48 hours.
- Check every new medicine with your pharmacist first, since common ones like fluconazole, omeprazole, metoprolol and metformin can need dose changes.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Fedratinib.
Inrebic can cause serious, sometimes fatal brain problems called encephalopathy, including Wernicke's encephalopathy. This is a neurologic emergency caused by low thiamine (vitamin B1).
Your doctor should check your thiamine level before you start. Inrebic should not be started if you are deficient. You should take a thiamine supplement every day during treatment, with levels rechecked as needed. Watch for confusion, memory trouble, changes in alertness, unsteady walking, or eye movement problems and double vision. If any of these occur, get medical help immediately. Treatment is stopped and thiamine is given by injection or IV.
Patient Information Guide for Fedratinib
What It’s Used For
Fedratinib is used for one condition, myelofibrosis, in adults.
- Inrebic is used for intermediate-2 or high-risk primary myelofibrosis.
- Inrebic is also used for secondary myelofibrosis that developed after polycythemia vera or essential thrombocythemia.
How It Works
Fedratinib is a kinase inhibitor, meaning it blocks enzymes that send growth signals inside cells. It is selective for JAK2, which is abnormally active in myelofibrosis and related bone marrow disorders. It also acts against FLT3.
In lab and animal studies, blocking these signals reduced abnormal cell growth and improved spleen size, scarring and survival.
Drug Class
WHO drug family
- Janus-associated kinase (JAK) inhibitors
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)None. The FDA’s index lists no class of any kind for Fedratinib.
The main drug class the FDA gives it. It is the class named on the drug’s label.
What It Does in the Body
Physiologic effect (PE)None listed for Fedratinib in the FDA’s index.
From our Patient Information GuideFedratinib is a kinase inhibitor, meaning it blocks enzymes that send growth signals inside cells. It is selective for JAK2, which is abnormally active in myelofibrosis and related bone marrow disorders. It also acts against FLT3. Read How Fedratinib Works
A change it makes in how the body works.
Drug Family
WHO ATC classification- Janus-associated kinase (JAK) inhibitors
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification, from the U.S. National Library of Medicine’s RxClass. Reference only, not medical advice.
Dosage
Inrebic is a capsule taken by mouth once daily, with or without food. A high-fat meal may ease nausea and vomiting.
Your doctor will check your platelet count and other labs before and during treatment.
- You will take thiamine (vitamin B1) daily while on treatment.
- Missed a dose? Take your next dose the following day.
- If you cannot swallow capsules, the contents can be mixed with Ensure Plus and taken within 2 hours.
- Your dose may be lowered for strong CYP3A4 inhibitor use, severe kidney impairment, or side effects.
Follow your prescriber's directions and the label.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Myelofibrosis (a bone marrow disease)
Adults Usual dose 400 mg once a day
- 400 mg taken orally once daily, with or without food (capsules 100 mg each)
Good to know
Thiamine 100 mg orally daily prophylaxis for all patients
Adults taking strong CYP3A4 inhibitor medicines Starting dose 200 mg once a day
- If the inhibitor is stopped, increase to 300 mg once daily during the first two weeks after discontinuation, then to 400 mg once daily thereafter as tolerated
Good to know
Strong CYP3A4 inhibitor coadministration
Adults with low platelet counts Dose 100 mg daily
- Interrupt dose until resolved to Grade 2 or lower or baseline.
- Restart dose at 100 mg daily below the last given dose.
Good to know
Discontinue if unable to tolerate 200 mg daily
Adults with low neutrophil counts Dose 100 mg daily
- Interrupt dose until resolved to Grade 2 or lower or baseline.
- Restart dose at 100 mg daily below the last given dose.
Good to know
Consider dose reductions for patients who become transfusion-dependent
Adults with severe nausea, vomiting or diarrhea Dose 100 mg daily
- Interrupt dose until resolved to Grade 1 or lower or baseline.
- Restart dose at 100 mg daily below the last given dose.
Adults with other severe side effects Dose 100 mg daily
- Interrupt dose until resolved to Grade 1 or lower or baseline.
- Restart dose at 100 mg daily below the last given dose.
Adults with severe kidney problems Usual dose 200 mg once a day
Good to know
CLcr 15 mL/min to 29 mL/min by Cockcroft-Gault
CrCl means creatinine clearance, a measure of how well the kidneys work.
Special Situations
If your test results change during treatment
Your doctor checks your test results during treatment and decides whether to change, pause or stop your dose. Never change your dose on your own.
Grade 3 or higher ALT, AST, or bilirubin elevation
Interrupt dose until resolved to Grade 1 or lower or baseline. Restart dose at 100 mg daily below the last given dose.
Monitor ALT, AST, and bilirubin more frequently; if Grade 3 or higher elevation recurs, discontinue Inrebic
ALT means alanine aminotransferase, a liver enzyme measured in a blood test.
AST means aspartate aminotransferase, a liver enzyme measured in a blood test.
Side Effects
The most common side effects are stomach-related and blood-related.
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Anemia (low red blood cells)
- Fatigue
- Low platelets (thrombocytopenia)
- Constipation
- Muscle spasms
When to get medical help
- Get emergency help right away for confusion, memory problems, changes in alertness, unsteady walking, or eye movement problems or double vision. These can be signs of Wernicke's encephalopathy.
- Call your doctor if you have severe or ongoing diarrhea, nausea or vomiting, especially if it does not improve within 48 hours.
- Call your doctor about unusual bleeding or bruising, or signs of severe anemia such as marked tiredness.
- Tell your doctor promptly about eye pain, redness, sensitivity to light, floaters or decreased vision. These can be signs of uveitis (eye inflammation).
- Seek help for symptoms of blood clots, heart attack or stroke.
- Call your doctor if you have yellowing of the skin or eyes or severe stomach pain, which may point to liver or pancreas problems.
- Do not stop Inrebic suddenly on your own. Symptoms can flare, including fever, trouble breathing and low blood pressure.
Warnings and Precautions
- Encephalopathy including Wernicke's: a serious, sometimes fatal brain problem tied to low thiamine. Daily thiamine and lab checks are required.
- Low blood counts: anemia and low platelets are common and may need dose changes or transfusions.
- Stomach upset: very common, and anti-nausea and anti-diarrhea medicines are often used.
- Liver, amylase and lipase increases: monitored with blood tests.
- Uveitis: eye inflammation that can show up months into treatment.
- Heart events, clots and secondary cancers: seen with another drug in this class in rheumatoid arthritis. Risk is higher in current or past smokers.
- Stopping suddenly: symptoms can flare, so talk to your care team first.
Interactions
Many interactions involve how the liver processes fedratinib.
- Strong CYP3A4 inhibitors (such as ketoconazole): raise fedratinib levels, so a lower dose may be needed.
- Strong and moderate CYP3A4 inducers (such as rifampin, efavirenz): lower levels and may reduce effectiveness, so avoid them.
- Fluconazole: raises levels, so closer monitoring is needed.
- Drugs cleared by CYP3A4, CYP2C19 or CYP2D6: levels may rise, so doses may need adjusting.
- Metformin and similar drugs cleared by the kidneys: may build up, so doses may need adjusting.
- Ruxolitinib: must be tapered off before starting Inrebic.
Interactions Listed in the FDA-Approved Label
From the Fedratinib prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
Strong CYP3A4 inhibitorsWhat happensIncrease fedratinib exposure, which may increase the risk of adverse reactions.What to doConsider alternative therapies that do not strongly inhibit CYP3A4; alternatively reduce the INREBIC dose.
-
Strong and moderate CYP3A4 inducersWhat happensCan decrease fedratinib exposure and may reduce effectiveness of INREBIC.What to doAvoid use with INREBIC.
-
Dual CYP3A4 and CYP2C19 inhibitorsWhat happensIncrease fedratinib exposure, which may increase the risk of adverse reactions.What to doMore intensive safety monitoring and, if necessary, INREBIC dose modifications based on adverse reactions.
-
CYP3A4, CYP2C19, or CYP2D6 substrate drugsWhat happensINREBIC increases the concentrations of these drugs, which may increase their adverse reactions.What to doMonitor for adverse reactions and adjust the dose of these drugs as necessary.
-
OCT2 and MATE1/2-K substrate drugs For example: metforminWhat happensINREBIC can decrease renal clearance of these drugs.What to doMonitor for adverse reactions and consider dose modifications of these drugs as necessary.
Read the label’s full interactions text
7 DRUG INTERACTIONS • Strong CYP3A4 Inhibitors: Reduce INREBIC dose as recommended. • Strong and Moderate CYP3A4 Inducers: Avoid use of INREBIC. • CYP3A4, CYP2C19, or CYP2D6 Substrates: Dose modifications of substrates drugs may be needed. • OCT2 and MATE1/2-K Substrates: Dose modifications of substrate drugs may be needed. 7.1 Effect of Other Drugs on INREBIC Strong CYP3A4 Inhibitors Coadministration of INREBIC with a strong CYP3A4 inhibitor increases fedratinib exposure. Increased exposure may increase the risk of adverse reactions. Consider alternative therapies that do not strongly inhibit CYP3A4 activity. Alternatively, reduce the dose of INREBIC when administering with a strong CYP3A4 inhibitor. Strong and Moderate CYP3A4 Inducers Coadministration of INREBIC with a strong or moderate CYP3A4 inducer can decrease fedratinib exposure. Decreased exposure may reduce the effectiveness of INREBIC. Avoid INREBIC with strong and moderate CYP3A4 inducers. Dual CYP3A4 and CYP2C19 Inhibitors Coadministration of INREBIC with a dual CYP3A4 and CYP2C19 inhibitor increases fedratinib exposure. Increased exposure may increase the risk of adverse reactions. Due to potential increase of exposure, patients taking concomitant dual CYP3A4 and CYP2C19 inhibitors require more intensive safety monitoring and, if necessary, dose modifications of INREBIC based on adverse reactions. 7.2 Effect of INREBIC on Other Drugs CYP3A4, CYP2C19, or CYP2D6 Substrate Drugs Coadministration of INREBIC with drugs that are CYP3A4 substrates, CYP2C19 substrates, or CYP2D6 substrates increases the concentrations of these drugs, which may increase the risk of adverse reactions of these drugs.
Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- There are no listed contraindications.
- Thiamine must be checked and corrected before starting.
- Severe kidney impairment needs a lower dose, and moderate impairment needs closer monitoring.
- Pregnancy: no human data, and animal studies showed developmental effects. Your doctor will weigh benefits and risks.
- Do not breastfeed during treatment and for at least 1 month after the last dose.
- Not established for children.
- Older adults had no overall differences in safety or effectiveness.
- Tell your doctor if you smoke or have a history of cancer, heart disease or clots.
Overdose
If you take too much Inrebic, consider contacting the Poison Help line at 1-800-222-1222 or a medical toxicologist for guidance.
Half-Life and How Your Body Processes It
Fedratinib reaches peak levels about 3 hours after a dose and builds up to steady levels within about 15 days of daily dosing. Food changes absorption only modestly. It is broken down mainly by liver enzymes (CYP3A4, CYP2C19 and FMO3) and cleared mostly in the feces. It has a long effective half-life of about 41 hours, and a terminal half-life of about 114 hours. Levels are higher in people with moderate to severe kidney impairment.
Storage
Store below 30°C (86°F).
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Supplements and Herbs That Interact With Fedratinib
From the licensed clinical database we use, rolled up per supplement, most serious first.177 supplements and herbal products have documented interactions with Fedratinib in the licensed clinical database we use.
Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.
- 6Major
- 132Moderate
- 39Minor
- ACTIVATED CHARCOALMajor
- BEERMajor
- GRAPEFRUITMajor
- SIBERIAN COCKLEBURMajor
- ST. JOHN'S WORTMajor
- WINEMajor
- 7,8-BENZOFLAVONEModerate
- ACACIA RIGIDULAModerate
Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Fedratinib: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Fedratinib — the kind of thing our pharmacy team would talk through with you at the counter.
What is fedratinib used for?
What happens if I miss a dose of fedratinib?
Why do I have to take thiamine with fedratinib?
What side effects should I expect with fedratinib?
Can I stop fedratinib suddenly?
Can I take fedratinib with other medicines or while pregnant or breastfeeding?
Is fedratinib available over the counter?
When was fedratinib first available?
What is the brand name of fedratinib?
What is the generic name of Inrebic?
What strengths does fedratinib come in?
Is there a fedratinib shortage?
Where can I read the fedratinib prescribing information (package insert)?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Fedratinib
Skip the scrolling. Ask in your own words and get an answer from Fedratinib’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Fedratinib’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Fedratinib on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Fedratinib Forms and Strengths (How It Comes)
Fedratinib comes in 1 dose form, the capsule. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Fedratinib inactive ingredients by manufacturer.
Capsule
How this form is used
- Inrebic is used for adults with intermediate-2 or high-risk primary or secondary myelofibrosis.
- Inrebic is taken by mouth once daily, with or without food.
- Inrebic taken with a high-fat meal may reduce nausea and vomiting.
- If you cannot swallow Inrebic capsules whole or have a nasogastric tube, the contents can be mixed with Ensure Plus and given within 2 hours.
- If an Inrebic dose is missed, take the next dose the following day.
Fedratinib on the U.S. Market: Products, Makers and Brands
How Fedratinib appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 1 Fedratinib product record with the FDA, mostly as capsule; the earliest marketing or approval year on record is 2019. The one brand name in the directory today is Inrebic; the rest are generics.
Compare Fedratinib Products
A representative set of FDA-listed product records for Fedratinib — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 100 mg | Oral | Celgene Corporation | NDA | View NDC → |
Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Fedratinib NDCs →
Fedratinib Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Fedratinib — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Fedratinib are diarrhoea, death, nausea; about 51% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Fedratinib in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Fedratinib FDA Approval History
How Fedratinib went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Fedratinib was first approved by the FDA in 2019 (Brand: INREBIC · Bristol-myers). It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Fedratinib Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Fedratinib recalls since July 2021.
✅No Fedratinib recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Fedratinib in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 1
- Strengths
- 1
- Forms in current FDA listings
- 1 of 1
RxCUI 2197490 -
Dose form (SCDF) Oral CapsuleIn current FDA listings
RxCUI 2197494Its strength (SCD)-
100 mg
RxCUI 2197495
-
100 mg
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Fedratinib Supply and Shortage Status
Whether Fedratinib is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Fedratinib Brand Names
Fedratinib has one brand name on record: Inrebic. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Fedratinib: Manufacturers and Labelers
One company lists Fedratinib products with the FDA. By number of product records, the largest are Celgene Corporation. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Fedratinib Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Celgene Corporation is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →